48 Advances in multiplexed ion beam imaging (MIBI) for immune profiling of the tumor microenvironment
BackgroundMultiplexed ion beam imaging (MIBI) combines time-of-flight secondary ion mass spectrometry (ToF-SIMS) with metal labeled antibodies to image 40+ proteins in a single scan at subcellular spatial resolution. Here, we show that the recently released MIBIscope provides improved sensitivity fo...
Saved in:
Published in | Journal for immunotherapy of cancer Vol. 8; no. Suppl 3; p. A51 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.11.2020
BMJ Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundMultiplexed ion beam imaging (MIBI) combines time-of-flight secondary ion mass spectrometry (ToF-SIMS) with metal labeled antibodies to image 40+ proteins in a single scan at subcellular spatial resolution. Here, we show that the recently released MIBIscope provides improved sensitivity for detecting immune checkpoint markers and offers greater throughput at higher resolution than the alpha instrument.MethodsSerial sections from three FFPE NSCLC samples, in addition to a control slide consisting of various unremarkable tissues, were stained with a panel of 25 metal labeled antibodies. The tissue was imaged at subcellular resolution using the MIBIscope and the alpha instrument. Masses of detected species were assigned to target biomolecules given the unique label of each antibody and multi-step processing was used to create images. Cell classification was performed using two complementary methods that differed in the need for cell segmentation to phenotypically characterize the tissue environments and quantify marker expression.ResultsReplicate regions of interest (ROIs) were collected on both instruments with similarly sized ROIs acquired in 17 minutes with the MIBIscope compared to 280 minutes with the alpha instrument. Fourier Ring Correlation (FRC) showed the resolution to be greater on the MIBIscope as compared to the alpha instrument with FRC also demonstrating uniform resolution across an ROI 2.5X greater in size. Even with the 16X greater speed of the MIBIscope, the signal of the 25 markers across replicate ROIs was increased (y=x^1.07) and showed similar expression patterns to those observed on the alpha instrument (figure 1). This resulted in greater sensitivity to markers with low expression, such as checkpoint markers. Eleven cell populations were classified across the ROIs utilizing two methods, with both methods showing a similar frequency of tumor cells and B, T, and myeloid cell subsets between instruments. Segmentation enabled the number of cells within a population to be calculated but defining boundaries is laborious and signal from neighboring cells can result in misclassification. Performing classification at the pixel level, without segmentation, enabled the fraction of the tissue that is tumor or any other cell type to be rapidly determined.Abstract 48 Figure 1Comparison of images acquired between instrumentsThe signal intensity is greater on the MIBIscope and shows a similar staining pattern as achieved by the alpha instrument. Shown are 3 overlays from a single scan from replicate ROIs of an NSCLC sample displayed with the same contrast settings.ConclusionsThe MIBIscope enables the phenotypic characterization of tumor and non-tumor microenvironments. Co-expression of markers can be used to classify tumor and immune populations and to quantify the expression of markers associated with immune suppression. The increased sensitivity and throughput of the MIBIscope, in combination with the 40-parameter capability and subcellular resolution, provides a platform uniquely suited to understanding the complex tumor immune landscape. |
---|---|
AbstractList | BackgroundMultiplexed ion beam imaging (MIBI) combines time-of-flight secondary ion mass spectrometry (ToF-SIMS) with metal labeled antibodies to image 40+ proteins in a single scan at subcellular spatial resolution. Here, we show that the recently released MIBIscope provides improved sensitivity for detecting immune checkpoint markers and offers greater throughput at higher resolution than the alpha instrument.MethodsSerial sections from three FFPE NSCLC samples, in addition to a control slide consisting of various unremarkable tissues, were stained with a panel of 25 metal labeled antibodies. The tissue was imaged at subcellular resolution using the MIBIscope and the alpha instrument. Masses of detected species were assigned to target biomolecules given the unique label of each antibody and multi-step processing was used to create images. Cell classification was performed using two complementary methods that differed in the need for cell segmentation to phenotypically characterize the tissue environments and quantify marker expression.ResultsReplicate regions of interest (ROIs) were collected on both instruments with similarly sized ROIs acquired in 17 minutes with the MIBIscope compared to 280 minutes with the alpha instrument. Fourier Ring Correlation (FRC) showed the resolution to be greater on the MIBIscope as compared to the alpha instrument with FRC also demonstrating uniform resolution across an ROI 2.5X greater in size. Even with the 16X greater speed of the MIBIscope, the signal of the 25 markers across replicate ROIs was increased (y=x^1.07) and showed similar expression patterns to those observed on the alpha instrument (figure 1). This resulted in greater sensitivity to markers with low expression, such as checkpoint markers. Eleven cell populations were classified across the ROIs utilizing two methods, with both methods showing a similar frequency of tumor cells and B, T, and myeloid cell subsets between instruments. Segmentation enabled the number of cells within a population to be calculated but defining boundaries is laborious and signal from neighboring cells can result in misclassification. Performing classification at the pixel level, without segmentation, enabled the fraction of the tissue that is tumor or any other cell type to be rapidly determined.Abstract 48 Figure 1Comparison of images acquired between instrumentsThe signal intensity is greater on the MIBIscope and shows a similar staining pattern as achieved by the alpha instrument. Shown are 3 overlays from a single scan from replicate ROIs of an NSCLC sample displayed with the same contrast settings.ConclusionsThe MIBIscope enables the phenotypic characterization of tumor and non-tumor microenvironments. Co-expression of markers can be used to classify tumor and immune populations and to quantify the expression of markers associated with immune suppression. The increased sensitivity and throughput of the MIBIscope, in combination with the 40-parameter capability and subcellular resolution, provides a platform uniquely suited to understanding the complex tumor immune landscape. BackgroundMultiplexed ion beam imaging (MIBI) combines time-of-flight secondary ion mass spectrometry (ToF-SIMS) with metal labeled antibodies to image 40+ proteins in a single scan at subcellular spatial resolution. Here, we show that the recently released MIBIscope provides improved sensitivity for detecting immune checkpoint markers and offers greater throughput at higher resolution than the alpha instrument.MethodsSerial sections from three FFPE NSCLC samples, in addition to a control slide consisting of various unremarkable tissues, were stained with a panel of 25 metal labeled antibodies. The tissue was imaged at subcellular resolution using the MIBIscope and the alpha instrument. Masses of detected species were assigned to target biomolecules given the unique label of each antibody and multi-step processing was used to create images. Cell classification was performed using two complementary methods that differed in the need for cell segmentation to phenotypically characterize the tissue environments and quantify marker expression.ResultsReplicate regions of interest (ROIs) were collected on both instruments with similarly sized ROIs acquired in 17 minutes with the MIBIscope compared to 280 minutes with the alpha instrument. Fourier Ring Correlation (FRC) showed the resolution to be greater on the MIBIscope as compared to the alpha instrument with FRC also demonstrating uniform resolution across an ROI 2.5X greater in size. Even with the 16X greater speed of the MIBIscope, the signal of the 25 markers across replicate ROIs was increased (y=x^1.07) and showed similar expression patterns to those observed on the alpha instrument (figure 1). This resulted in greater sensitivity to markers with low expression, such as checkpoint markers. Eleven cell populations were classified across the ROIs utilizing two methods, with both methods showing a similar frequency of tumor cells and B, T, and myeloid cell subsets between instruments. Segmentation enabled the number of cells within a population to be calculated but defining boundaries is laborious and signal from neighboring cells can result in misclassification. Performing classification at the pixel level, without segmentation, enabled the fraction of the tissue that is tumor or any other cell type to be rapidly determined.Abstract 48 Figure 1Comparison of images acquired between instrumentsThe signal intensity is greater on the MIBIscope and shows a similar staining pattern as achieved by the alpha instrument. Shown are 3 overlays from a single scan from replicate ROIs of an NSCLC sample displayed with the same contrast settings.[Figure omitted. See PDF]ConclusionsThe MIBIscope enables the phenotypic characterization of tumor and non-tumor microenvironments. Co-expression of markers can be used to classify tumor and immune populations and to quantify the expression of markers associated with immune suppression. The increased sensitivity and throughput of the MIBIscope, in combination with the 40-parameter capability and subcellular resolution, provides a platform uniquely suited to understanding the complex tumor immune landscape. |
Author | Mignault, Andre Geyer, Felipe Finck, Rachel Finn, Jessica Deeds, James Zhang, Yi Sigal, Yari Hav, Monirath Ptacek, Jason Giedt, Jimmy McLaughlin, Margaret Tarolli, Jay Gu, Jane Aksoy, Murat |
Author_xml | – sequence: 1 givenname: Jason surname: Ptacek fullname: Ptacek, Jason organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 2 givenname: Felipe surname: Geyer fullname: Geyer, Felipe organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 3 givenname: Andre surname: Mignault fullname: Mignault, Andre organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 4 givenname: James surname: Deeds fullname: Deeds, James organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 5 givenname: Jimmy surname: Giedt fullname: Giedt, Jimmy organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 6 givenname: Jane surname: Gu fullname: Gu, Jane organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 7 givenname: Margaret surname: McLaughlin fullname: McLaughlin, Margaret organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 8 givenname: Yari surname: Sigal fullname: Sigal, Yari organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 9 givenname: Jay surname: Tarolli fullname: Tarolli, Jay organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 10 givenname: Murat surname: Aksoy fullname: Aksoy, Murat organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 11 givenname: Yi surname: Zhang fullname: Zhang, Yi organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 12 givenname: Monirath surname: Hav fullname: Hav, Monirath organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 13 givenname: Rachel surname: Finck fullname: Finck, Rachel organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA – sequence: 14 givenname: Jessica surname: Finn fullname: Finn, Jessica organization: Novartis Institutes for Biomedical Resea, Cambridge, MA, USA |
BookMark | eNpFkc9u1DAQxi0EEm3pM2CJS3tI63-JJ8eyKjRSKw7s3XKcyeJVYm-dpGpvXHhRngSnC-Iw8nhm9M1n_07J2xADEvKRsyvOZXW997MrBBOs-N5sN2tyxZiCN-REsJIXXInqPTmfpj1jjDMpAeCE7BT8_vnrpnuyweFEfaDjMsz-MOAzdtTHQFu0I_Wj3fmwoxcPzefmkvYx5dK4BKSHFHs_rL3Y0_kH0nkZc3f0LkUMTz7FMGKYP5B3vR0mPP97npHtl9vt5q64__a12dzcFy2Xui6UBKwsKu049Mpi1bvadjKH4sIp6FwPwkKrS1GruuSt1EzUXaugtVW-nZHmKNtFuzeHlH2nFxOtN6-FmHbGptm7AY1mnKNGp1uUSoO2YDmHCnhdg-qhzFqfjlr5iY8LTrPZxyWF7N6IspT5F6Ws85Q4TrXj_4WcmRWJWZGYlYT5h8SsSOQf0V2Drw |
ContentType | Journal Article |
Copyright | Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS DOA |
DOI | 10.1136/jitc-2020-SITC2020.0048 |
DatabaseName | ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Directory of Open Access Journals |
DatabaseTitle | Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X7 name: ProQuest_Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2051-1426 |
EndPage | A51 |
ExternalDocumentID | oai_doaj_org_article_7011e7ec7be34787a8a1186819984f85 |
GroupedDBID | -A0 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABDBF ABUWG ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AFGXO AFKRA AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PIMPY PQQKQ PROAC PSQYO RBZ RMJ ROL RPM RSV SOJ UKHRP 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS |
ID | FETCH-LOGICAL-b1379-438e6ae47c18f4ae6fc9ad39ad412c48dcf82a8b75294951b37029db48ba61b3 |
IEDL.DBID | 9YT |
IngestDate | Thu Jul 04 21:08:15 EDT 2024 Fri Sep 13 07:56:01 EDT 2024 Wed Aug 21 03:39:28 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 3 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1379-438e6ae47c18f4ae6fc9ad39ad412c48dcf82a8b75294951b37029db48ba61b3 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/jitc-2020-SITC2020.0048 |
PQID | 2553000339 |
PQPubID | 2040222 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7011e7ec7be34787a8a1186819984f85 proquest_journals_2553000339 bmj_primary_10_1136_jitc_2020_SITC2020_0048 |
PublicationCentury | 2000 |
PublicationDate | 20201100 20201101 2020-11-01 |
PublicationDateYYYYMMDD | 2020-11-01 |
PublicationDate_xml | – month: 11 year: 2020 text: 20201100 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Journal for immunotherapy of cancer |
PublicationYear | 2020 |
Publisher | BMJ Publishing Group LTD BMJ Publishing Group |
Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
SSID | ssj0001033888 |
Score | 2.1728702 |
Snippet | BackgroundMultiplexed ion beam imaging (MIBI) combines time-of-flight secondary ion mass spectrometry (ToF-SIMS) with metal labeled antibodies to image 40+... |
SourceID | doaj proquest bmj |
SourceType | Open Website Aggregation Database Publisher |
StartPage | A51 |
SubjectTerms | Immunotherapy Ion beams |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF6kB_EiPrFaZQ8eFIl2s9vs7lFFsUK9WMHbsq9IC0nFtuDRi3_UX-JMkkrBgxcPgWQ3kPDNJDuzM_MNIce-y23gUSC_nUyE1z5xqpclubQ2htANgWE18uAhu3sS98-956VWX5gTVtMD18BdSFDAKKOXLnIkkrHKMqR4x9owkauavZT1lpypanelC66XUk1CF-PZxXg086AS4Cw99ofXeHKO2gtLiivGDWH_r_9xtcjcbpD1xjqkl_VbbZKVWG6R1UET_94mL0J9fXxe1nH7KR2VdJEQ-B4DBYipi7ago6LqPURPBv2r_ikFuxSGinkZad2iG-cmOQXbj87mBcwWmJa3VPO2Q4a3N8Pru6RplZA4xqVOBFcxs1FIz1QubMxyr0EGcAiWeqGCz1VqlZO9VINLxByX3VQHJ5SzGVztklY5KeMeobkIOmjOorMOo8VOeC9sDhDqNEjm2-QMADOvNReGqXwInhmE1yCqZgGvQXjb5AqB_bkdyayrARCxaURs_hJxm3QWYjHNFzY1KfY7wk50ev8_nnFA1irlqKoMO6Q1e5vHQzA3Zu6o0qxvNrPQHQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBZ5QMil9JFSp07RoYeWsrG1klfSKcQhwS44lNaB3IReGxzYdRKvIcdc-kf7Szqz1jaFQg8LWmn38s1oNKN5EfLRD7kNPAqsbycz4bXPnBoVWSmtjSEMQ2CYjTy7LCZX4uv16HqLTLpcGAyr7GRiK6jD0uMd-SDH_jbYeUwPrMNbAN8MTu7uM-wfhX7W1Exjm-zmTKDDdnd8fvnt-_N9C_wK1l4K8WK8GNwuGg9MAubTj-n8DAfHyM9wyLjqNpXw_0dCt8fOxUvyIumL9HRD4FdkK9avyd4secTfkBuhfj39PN148ld0UdMuRPAxBgqgUxdtRRdV242IfppNx9PPFDRVmKrWdaSbpt24tiwpaIO0WVewWmGg3l9ZcAdkfnE-P5tkqXlC5hiXOhNcxcJGIT1TpbCxKL0GqsAjWO6FCr5UuVVOjnINRhJzXA5zHZxQzhbw9pbs1Ms6viO0FEEHzVl01qH_2AnvhS0BQp0HyXyPfAHAzN2mOoZprQpeGITXIKqmg9cgvD0yRmD_fI7lrduJ5cONSbvFSJA6UUYvXeRYPcgqy7CuPyYEilKNeqTfkcWkPbcyzxxy-P_l92S_JXubUdgnO83DOh6BatG4D4lrfgM4Rc3X priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LTxsxELYKlRAXVAqIUIp86AGEFrJrZ20fUAVREakULiQSN8uvRYnYTZuHlN648Ef7S5jZOIAE6qmHlXbtXa30zdiesWfmI-SbazLjWeBY304k3CmXWNnKk0IYE7xvep9iNnL3Or_q85-3rduXzLoI4ORd1w75pPrj-5P57z_fYcCfRUaS0-Fg6kDa4AfddHptvDlBxVwhHzPOOKp9N9r89cZLE7wyKWOs1z--h9XGlsNYy__NVF2vP5efyEY0HOn5QtKb5EOoPpO1bjwa3yJ3XP59eDxfHOlP6KCiy1jBefAU0Kc2mJIOypqWiB52OxedIwomKzSVsyrQBXs39o0KCmYhnc5K6C0xYu9VOtw26V3-6LWvksiikNiUCZVwJkNuAhculQU3IS-cAvHAxdPMceldITMjrWhlCryl1DLRzJS3XFqTw9MOWa1GVdgltOBeecXSYI3Fg2TLneOmAAhV5kXqGuQYANO_FmUydO1esFwjvBpR1Ut4NcLbIBcI7PPrWOe6bhiN73QcNlrA9BNEcMIGhmWEjDQpFvjHzEBeyFaD7C_Fope6ozOkQkKSOrX3P_7xhazXylEnIO6T1el4Fr6CJTK1B7VmPQF8Xdpc priority: 102 providerName: Scholars Portal |
Title | 48 Advances in multiplexed ion beam imaging (MIBI) for immune profiling of the tumor microenvironment |
URI | http://dx.doi.org/10.1136/jitc-2020-SITC2020.0048 https://www.proquest.com/docview/2553000339/abstract/ https://doaj.org/article/7011e7ec7be34787a8a1186819984f85 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9tAEB7ygNJLSV_UaWL20ENLUevVrrW7xzgkxAWH0rrgnpZ9qTggpSQ29NhL_mh-SWbWclpICOQgIe1KIL7Zx4xm5huAd2EgXBRJEr-dKmQwofB6WBW1ci7FOIiRUzby5LQ6-SG_zIazDeD3e_C5qD6fzRcBZYlWzvfx9JAuPtGw24TtEnXdXLTg5_Tfb5UB2lxad5FcD7yPe4lvzjqm_jsLcd5djnfgWacWsoOVHJ_DRmpfwJNJ5_h-Cb-kvv57dbBy2F-yecvWkYB_UmSILfPJNWze5KJD7P1kPBp_YKiQYlOzbBNb1eamvvOaodLHFssGexuKx_sv2e0VTI-PpocnRVcjofBcKFNIoVPlklSB61q6VNXBIPh4SF4GqWOodem0V8PSoC3EvVCD0kQvtXcV3r2Grfa8TW-A1TKaaARP3nlyE3sZgnQ1QmjKqHjowUcEzP5ekWDYbDyIyhK8llC1a3gtwduDEQF7-zixWOcGFK3tJoVVuLgklYLySRBJkNOOE30_5f3JWg97sLcWi-2m1qUtqdARlaAzu4_6orfwNI-CnEe4B1uLi2XaR4Vi4fuwqWaqnwdSH7ZHR6dfv_WzcY7nidQ3IdfIMg |
link.rule.ids | 315,786,790,870,2115,12083,21416,24346,27582,27583,27957,27958,31754,33779,43345,43840,74102,74659 |
linkProvider | BMJ Publishing Group Ltd |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LTxsxELYKlYALgraIFCg-9EBVLcRrZ22fKkBFCRAuBCk3y69FQdoNJYnUYy_8UX5JZzYOICFxWGnX3tPn8XjG8_gI-e7b3AYeBfa3k5nw2mdOdYqslNbGENohMKxG7l8V3RtxPuwM04XbJKVVLnRio6jD2OMd-VGO_DbIPKZ_3f_JkDUKo6uJQmOJfBScC0zpk0P5cscCv4OHl9K6GC-O7kZTD4IBLtN1b3CKL4cow3CwuOoute1_o5Wbo-Zsg6wnG5Eezxd1k3yI9Sey0k9R8M_kVqinf4_H8-j9hI5qukgL_BsDBaCpi7aio6phIKIH_d5J7wcF6xSGqlkd6ZyoG-fGJQULkE5nFcxWmJz3qvLtCxmc_R6cdrNEmJA5xqXOBFexsFFIz1QpbCxKr2El4BEs90IFX6rcKic7uQbHiDku27kOTihnC_jaIsv1uI7bhJYi6KA5i846jBk74b2wJUCo8yCZb5GfAJi5n3fEMI0nwQuD8BpE1SzgNQhvi5wgsM-_Y0vrZmD8cGvSDjESNE2U0UsXOXYMssoy7OWPRYCiVJ0W2V0si0n7bGJepOLr-9P7ZLU76F-ay97VxQ5Za0SgqSjcJcvTh1ncA9Ni6r418vMfcOPLpA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBZpAqGXkvRBnaaJDj20lK2tlbySTiUvE7d1KNQF34SewYFdp7ENPeaSP5pf0pm13BQKOSzsSruXT7OjGc3jI-Sd73EbeBTY304WwmtfONWviiStjSH0QmBYjTy6qM5_ii-T_iTnP81zWuVaJ7aKOsw8npF3S-S3QeYx3U05LeL76eDz9a8CGaQw0prpNJ6QLdgle8hmICfy4bwFPgVvL6d4MV51r6YLD0IC7tOP4fgEbz6hPMMm4-qr3ML_Pw3dbjuDHfIs24v0aLXAu2QjNs_J9ihHxF-QS6Hub--OVpH8OZ02dJ0i-DsGCqBTF21Np3XLRkTfj4bHww8ULFUYqpdNpCvSbpybJQrWIF0sa5itMVHvnyq4l2Q8OBufnBeZPKFwjEtdCK5iZaOQnqkkbKyS17AqcAlWeqGCT6q0ysl-qcFJYo7LXqmDE8rZCp5ekc1m1sTXhCYRdNCcRWcdxo-d8F7YBBDqMkjmO-QjAGauV90xTOtV8MogvAZRNWt4DcLbIccI7N_Xsb11OzC7uTT5bzEStE6U0UsXOXYPssoy7OuPBYEiqX6H7K-XxeR_bm4eJGTv8elDsg2iY74NL76-IU9bCWiLC_fJ5uJmGd-ClbFwB634_AHUo8_Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=48%E2%80%85Advances+in+multiplexed+ion+beam+imaging+%28MIBI%29+for+immune+profiling+of+the+tumor+microenvironment&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Yi+Zhang&rft.au=Jason+Ptacek&rft.au=Felipe+Geyer&rft.au=Andre+Mignault&rft.date=2020-11-01&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=8&rft.issue=Suppl+3&rft_id=info:doi/10.1136%2Fjitc-2020-SITC2020.0048&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_7011e7ec7be34787a8a1186819984f85 |